Radiation Oncologist, Director of Clinical Adaptive Therapy @UTSW
Dallas, TX
Joined April 2024
- Tweets296
- Following810
- Followers272
- Likes2.6K
Shahed Badiyan retweeted
My top 3 “most exciting” clinical observations from Day 1 of the MR-Linac Consortium:
1. Esophageal adenocarcinoma: Integrating adaptive MR-guided SBRT to gross disease after neoadjuvant FLOT appears feasible and safe. Two targets using an SIB approach: pre-treatment gross disease and residual gross disease. 3-mm PTV margins. Phase 1 outcomes are maturing.
2. Direct-to-Unit (DTU) workflows: DTU has expanded well beyond inpatient palliative care: prostate SBRT, GBM, liver metastases, and oligometastatic lymph nodes. This has the potential to dramatically increase access to MR-Linacs.
3. Early-stage glottic cancer: Twice-weekly SBRT (8.5 Gy × 5) appears feasible and safe. 2-mm PTV margins, except 4 mm CC. No CTV. The target can be tracked using the cricoid. Phase 1 outcomes are maturing.
Bonus:
3b. GBM: FLAIR changes that emerge during long-course RT may have prognostic and/or predictive value. Seen in ~5–10% of patients.
@BadiyanMD @CShahMD @SahgalArjun @DavidSherMD @jaydetsky @StevenLin_MDPhD
Shahed Badiyan retweeted
We are hiring radiation therapists for both our Dallas and upcoming Fort Worth locations. Be part of a team committed to clinical excellence, innovation, and patient-centered care!
Dallas📍: bit.ly/3WaRl3F
Fort Worth📍: bit.ly/4eW26Ny
ALT A graphic for a radiation therapist position opening with statistics on the department.
ALT A radiation oncology building.
ALT A rendering of a radiation oncology building.
Shahed Badiyan retweeted
🔥AGITG MASTERPLAN🔥
Borderline resectable or Locally advanced PDAC
n=75
🔍Randomized
3m mFOLFIRINOX or Gem+nab-Paclitaxel alone +/- SBRT (40 Gy/5 fx)
Primary endpoint: locoregional recurrence
🚨SBRT had improved:
✅12 m LRR: 20% vs. 50%
✅mOS 22m vs. 14 m
#ESMO26
Shahed Badiyan retweeted
NRG will be hosting a webinar for 2 of our active studies in the NRG GI CRC space. Learn more about NRG-GI011 "LAP100" in #PancreaticCancer & NRG-GI012 "HELIO-RT" in hepatocellular carcinoma with macrovascular invasion #LiverTwitter - Register here: acr-org.zoom.us/webinar/regi…
Shahed Badiyan retweeted
The 2026 Pancreatic Cancer Patient Summit will highlight the latest research, clinical trials, and innovations advancing pancreatic cancer care, while creating opportunities to connect, share knowledge, and learn from leaders in the field.
Register: bit.ly/4zbMVYy
ALT A graphic with two women standing together.
It Can Keep Cancer in Remission. Why Is No One Talking About It? nytimes.com/2026/10/06/well/… via @NYTimes
We need insurance coverage for exercise oncology interventions. Cost effective and improves outcomes for our patients.
Shahed Badiyan retweeted
👇As systemic therapy improves, local control matters more. We’re using RT w/ RASi on EXPAND and in trials upon oligoprogression. It's a new horizon for pancreatic cancer— pts benefit from evidence of added value to bring this opportunity to more. @PanCAN @utswcancer @UTSW_RadOnc
Trials already underway! The role of local therapy for mPDAC in the RASi era is only just beginning… @NiuSanford @DrShubhamPant @ACKoongMDPhD @PrajnanDasMD @Vince_BernPag @eugenekoay @ChadTangMD
Shahed Badiyan retweeted
Enjoyed this session & learned a lot!
Both TARE & SBRT can deliver ablative RT in HCC. Key q is which approach is best suited for a given pt/tumor.
Sharing some of my slides below re: decision-making b/w the 2 modalities.
TY to @GIcancerDoc & @EileenMOReilly for the invite.
Shahed Badiyan retweeted
Thoughtful read on how oncology rewards innovation.
Much of RT progress = precise & efficient tx, improving therapeutic ratio but reducing reimbursement. Systemic advances often =drugs given for yrs.
Current model rewards quantity/duration, but shouldn’t value reflect benefit?
How do we think about the cost of systemic therapy agents as compared to other cancer treatment modalities such as SBRT when considering value and is it time for a change?
jamanetwork.com/journals/jam…
#radonc @ASTRO_org @ASTRO_Chair @SameerKeoleMD @DrewMoghanaki
Shahed Badiyan retweeted
NRG will be hosting a webinar for 2 of our active studies in the NRG GI CRC space. Learn more about NRG-GI011 "LAP100" in #PancreaticCancer & NRG-GI012 "HELIO-RT" in hepatocellular carcinoma with macrovascular invasion #LiverTwitter - Register here: acr-org.zoom.us/webinar/regi…
Shahed Badiyan retweeted
GI003 HCC proton vs photon: no dif OS, PFS, Gr 3+ AEs.
Protons = 1 option in expanding RT toolbox (MRgRT, adaptive, etc) to optimize therapeutic ratio, & each case should be individualized by tumor & liver fxn.
But w neg RCT & $/access dif, photon RT should remain SOC. #ASTRO26
Shahed Badiyan retweeted
Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial
thelancet.com/journals/lanep…
Shahed Badiyan retweeted
Only 3 days away! Join us for the PULSAR Consortium Meeting at #ASTRO2026 in Boston. Registration is FREE, and CME credits are available.
🔗: bit.ly/4gSUews
📍: The Tower, 101 Arlington St, 4th Floor Library
🗓️: Monday, Sept. 28
🕕: 6-8 p.m.
ALT A graphic for a PULSAR Consortium Meeting with speakers and talk titles.
Shahed Badiyan retweeted
A look at the Nature Index 2026 ranking of the world’s leading healthcare institutions, based on 2025 research output.*
Here are the global Top 50
Shahed Badiyan retweeted
ASTRO is just a little over a week away! Stop by Lucky's Lounge next Sunday to connect and learn more about our medical residency program!
Attending @ASTRO_org and exploring residency opportunities? Come meet us at Lucky's Lounge on Sunday, September 27, starting at 6 p.m. Learn more about our program and connect with us. See you there!
ALT A graphic for a meet and greet with a building picture and headshots of leadership.
Shahed Badiyan retweeted
Register now for our 2026 Oncology Year in Review CME! bit.ly/4wVJHHR
This program will provide participants with the latest information available, as presented at the @ASCO meeting, @myESMO meeting, and other meetings that took place in 2026, from our experts.
ALT Close-up illustration of a cell with blue strands, accompanied by text: "Register Now, 2026 Oncology Year in Review CME, Saturday, Nov. 14, UT Southwestern Medical Center, Dallas, TX."
Shahed Badiyan retweeted
Advance your adaptive radiation therapy skills at our hands-on Ethos CBCT-guided ART course! We offer interactive treatment planning, workflow simulations, and expert guidance to help bring adaptive therapy into clinical practice.
More info: 📧 [email protected]
ALT A graphic for an Ethos ART Training Program with basic course info and pictures from a previous course.
Shahed Badiyan retweeted
Happening in 2 wks! Join us Sun 9/27, 4:45P #ASTRO26:
Making Sense of Trials in Community Rad Onc: From Headlines to High-Value Care
3 talks on Ph II trials, omission studies & novel RT technologies - practical frameworks for interpreting new data & translating into practice.
Shahed Badiyan retweeted
Join us Monday, Sept. 28 at #ASTRO2026 for the PULSAR Consortium Meeting! Hear from experts shaping the future of PULSAR and personalized radiation therapy. CME credits available.
Registration is free!
🔗: bit.ly/4gSUews
ALT A graphic for a PULSAR Consortium Meeting with speaker and event information.